Elisabetta Poluzzi

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5845786/publications.pdf

Version: 2024-02-01

147 papers	5,305 citations	108046 37 h-index	111975 67 g-index
150 all docs	150 docs citations	150 times ranked	6885 citing authors

#	Article	IF	Citations
1	Skin Toxicities with Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Signals from Disproportionality Analysis of the FDA Adverse Event Reporting System. American Journal of Clinical Dermatology, 2022, 23, 247-255.	3.3	18
2	Crystal nephropathy and amoxicillin: insights from international spontaneous reporting systems. Journal of Nephrology, 2022, 35, 1017-1027.	0.9	4
3	Evaluating sacubitril/valsartan as a treatment option for heart failure with reduced ejection fraction and preserved ejection fraction. Expert Opinion on Pharmacotherapy, 2022, 23, 303-320.	0.9	1
4	Medication Use and Costs Among Older Adults Aged 90ÂYears and Older in Italy. Frontiers in Pharmacology, 2022, 13, 818875.	1.6	3
5	Impact of nephrotoxic drugs on urinary biomarkers of renal function in very preterm infants. Pediatric Research, 2022, 91, 1715-1722.	1.1	5
6	Amyotrophic Lateral Sclerosis as an Adverse Drug Reaction: A Disproportionality Analysis of the Food and Drug Administration Adverse Event Reporting System. Drug Safety, 2022, 45, 663-673.	1.4	7
7	Impulse Control Disorders by Dopamine Partial Agonists: A Pharmacovigilance-Pharmacodynamic Assessment Through the FDA Adverse Event Reporting System. International Journal of Neuropsychopharmacology, 2022, 25, 727-736.	1.0	15
8	Global prevalence of antidepressant drug utilization in the community: protocol for a systematic review. BMJ Open, 2022, 12, e062197.	0.8	4
9	Liver Injury with Nintedanib: A Pharmacovigilanceâ€“Pharmacokinetic Appraisal. Pharmaceuticals, 2022, 15, 645.	1.7	5
10	The Changing Face of Drug-induced Adrenal Insufficiency in the Food and Drug Administration Adverse Event Reporting System. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e3107-e3114.	1.8	7
11	Time-Trends of Drug-Drug Interactions among Elderly Outpatients in the Piedmont Region (Italy): A Population-Based Study. International Journal of Environmental Research and Public Health, 2022, 19, 7353.	1.2	2
12	Post-Marketing Surveillance of CAR-T-Cell Therapies: Analysis of the FDA Adverse Event Reporting System (FAERS) Database. Drug Safety, 2022, 45, 891-908.	1.4	18
13	Drug-induced systemic lupus erythematosus: should immune checkpoint inhibitors be added to the evolving list?. Annals of the Rheumatic Diseases, 2021, 80, e120-e120.	0.5	15
14	Serious adverse events with tocilizumab: Pharmacovigilance as an aid to prioritize monitoring in COVIDâ€19. British Journal of Clinical Pharmacology, 2021, 87, 1533-1540.	1.1	40
15	SGLT2 inhibitors for heart failure with reduced ejection fraction: a real EMPEROR?. Expert Opinion on Pharmacotherapy, 2021, 22, 647-650.	0.9	1
16	Assessment of adverse reactions to Î±-lipoic acid containing dietary supplements through spontaneous reporting systems. Clinical Nutrition, 2021, 40, 1176-1185.	2.3	18
17	The chronic use of multiple photosensitizing drugs is associated with Breslow thickness in female melanoma patients: A bicentric retrospective study. Journal of the American Academy of Dermatology, 2021, 84, 1762-1764.	0.6	2
18	Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment. Breast Cancer Research and Treatment, 2021, 186, 219-227.	1.1	59

#	Article	IF	Citations
19	Antibiotic Use and Risk of Multiple Sclerosis: A Nested Case-Control Study in Emilia-Romagna Region, Italy. Neuroepidemiology, 2021, 55, 224-231.	1.1	4
20	Influenza Vaccination and Myo-Pericarditis in Patients Receiving Immune Checkpoint Inhibitors: Investigating the Likelihood of Interaction through the Vaccine Adverse Event Reporting System and VigiBase. Vaccines, 2021, 9, 19.	2.1	11
21	Authorsâ€™ Reply to Robert P. Giugliano and Colleaguesâ€™ Comment on: â€œDirect Oral Anticoagulants and Interstitial Lung Disease: Emerging Clues from Pharmacovigilanceâ€• Drug Safety, 2021, 44, 505-506.	1.4	1
22	Thromboembolic Events with Cyclin-Dependent Kinase 4/6 Inhibitors in the FDA Adverse Event Reporting System. Cancers, 2021, 13, 1758.	1.7	19
23	Identifying ethical values for guiding triage decisions during the COVID-19 pandemic: an Italian ethical committee perspective using Delphi methodology. BMJ Open, 2021, 11, e043239.	0.8	7
24	Serious adverse events with tedizolid and linezolid: pharmacovigilance insights through the FDA adverse event reporting system. Expert Opinion on Drug Safety, 2021, 20, 1421-1431.	1.0	9
25	Breakthrough invasive fungal infections in liver transplant recipients exposed to prophylaxis with echinocandins vs other antifungal agents: A systematic review and metaâ€analysis. Mycoses, 2021, 64, 1317-1327.	1.8	3
26	ROCCA observational study: Early results on safety of Sputnik V vaccine (Gam-COVID-Vac) in the Republic of San Marino using active surveillance. EClinicalMedicine, 2021, 38, 101027.	3.2	39
27	Pulmonary Embolism in a Patient With ADPKD Treated With Tolvaptan: From the Clinical Experience to the Analysis of the Food and Drug Administration Adverse Event Reporting System Registry. Kidney International Reports, 2021, 6, 2472-2477.	0.4	3
28	Impulsive conditions in Parkinson's disease: A pharmacosurveillance-supported list. Parkinsonism and Related Disorders, 2021, 90, 79-83.	1.1	5
29	COVID-19 Vaccination in Pregnancy, Paediatrics, Immunocompromised Patients, and Persons with History of Allergy or Prior SARS-CoV-2 Infection: Overview of Current Recommendations and Pre- and Post-Marketing Evidence for Vaccine Efficacy and Safety. Drug Safety, 2021, 44, 1247-1269.	1.4	85
30	Development of a Network-Based Signal Detection Tool: The COVID-19 Adversome in the FDA Adverse Event Reporting System. Frontiers in Pharmacology, 2021, 12, 740707.	1.6	5
31	Myopathy with DPP-4 inhibitors and statins in the real world: investigating the likelihood of drugâ€“drug interactions through the FDA adverse event reporting system. Acta Diabetologica, 2020, 57, 71-80.	1.2	18
32	Signal of potentially protective drugâ€“drug interactions from spontaneous reporting systems: proceed with caution. Acta Diabetologica, 2020, 57, 115-116.	1.2	4
33	Reduced neuropsychiatric events as â€œbeneficial reactionsâ€• to drugs: Seek associations with caution. Brain, Behavior, and Immunity, 2020, 84, 275-276.	2.0	4
34	The Complex Management of Atrial Fibrillation and Cancer in the COVID-19 Era: Drug Interactions, Thromboembolic Risk, and Proarrhythmia. Current Heart Failure Reports, 2020, 17, 365-383.	1.3	17
35	Challenges in Repurposing Drugs in COVID-19 Pandemic. Debating on Potential New Refinements. Frontiers in Pharmacology, 2020, 11, 559996.	1.6	4
36	Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance. Targeted Oncology, 2020, 15, 449-466.	1.7	86

#	Article	IF	Citations
37	Liver Injury with Ulipristal Acetate: Exploring the Underlying Pharmacological Basis. Drug Safety, 2020, 43, 1277-1285.	1.4	25
38	Baricitinib, JAK inhibitors and liver injury: a cause for concern in COVID-19?. Expert Opinion on Drug Safety, 2020, 19, 1367-1369.	1.0	11
39	Direct Oral Anticoagulants and Interstitial Lung Disease: Emerging Clues from Pharmacovigilance. Drug Safety, 2020, 43, 1191-1194.	1.4	9
40	Biomarkers of Kidney Injury in Very-low-birth-weight Preterm Infants: Influence of Maternal and Neonatal Factors. In Vivo, 2020, 34, 1333-1339.	0.6	9
41	â€˜Use of antipsychotics in children and adolescents: a picture from the ARITMO population-based European cohort studyâ€™. Epidemiology and Psychiatric Sciences, 2020, 29, e117.	1.8	21
42	Comparing the Prevalence of Polypharmacy and Potential Drug-Drug Interactions in Nursing Homes and in the Community Dwelling Elderly of Emilia Romagna Region. Frontiers in Pharmacology, 2020, 11, 624888.	1.6	12
43	Modified-Chronic Disease Score (M-CDS): Predicting the individual risk of death using drug prescriptions. PLoS ONE, 2020, 15, e0240899.	1.1	11
44	Risk of hospitalization from drug-drug interactions in the Elderly: real-world evidence in a large administrative database. Aging, 2020, 12, 19711-19739.	1.4	13
45	Prevalence and Determinants of Long-Term Utilization of Antidepressant Drugs: A Retrospective Cohort Study . Neuropsychiatric Disease and Treatment, 2020, Volume 16, 1157-1170.	1.0	12
46	Reply-Letter to the editor - The valuable support of spontaneous reporting systems in exploring safety profile of dietary supplements. Clinical Nutrition, 2020, 39, 3854-3855.	2.3	1
47	Title is missing!. , 2020, 15, e0240899.		0
48	Title is missing!. , 2020, 15, e0240899.		0
49	Title is missing!. , 2020, 15, e0240899.		0
50	Title is missing!. , 2020, 15, e0240899.		0
51	Drug-induced Kounis syndrome: A matter of pharmacovigilance. International Journal of Cardiology, 2019, 274, 381.	0.8	9
52	Use of antidepressants and the risk of Parkinson's disease in the Local Health Trust of Bologna: A historical cohort study. Journal of the Neurological Sciences, 2019, 405, 116421.	0.3	9
53	Patterns and trends of utilization of incretin-based medicines between 2008 and 2014 in three Italian geographic areas. BMC Endocrine Disorders, 2019, 19, 18.	0.9	4
54	Dapagliflozin and cardiovascular outcomes: anything else to DECLARE?. Expert Opinion on Pharmacotherapy, 2019, 20, 1087-1090.	0.9	4

#	Article	IF	Citations
55	Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System. Targeted Oncology, 2019, 14, 205-221.	1.7	72
56	Long-acting injectable antipsychotics: Six-month follow-up of new outpatient treatments in Bologna Community Mental Health Centres. PLoS ONE, 2019, 14, e0211938.	1.1	3
57	Serious Cutaneous Toxicities with Immune Checkpoint Inhibitors in the U.S. Food and Drug Administration Adverse Event Reporting System. Oncologist, 2019, 24, e1228-e1231.	1.9	30
58	Liver injury with drugs used for multiple sclerosis: A contemporary analysis of the FDA Adverse Event Reporting System. Multiple Sclerosis Journal, 2019, 25, 1633-1640.	1.4	21
59	The Role of European Healthcare Databases for Post-Marketing Drug Effectiveness, Safety and Value Evaluation: Where Does Italy Stand?. Drug Safety, 2019, 42, 347-363.	1.4	65
60	Hepatitis B vaccination and the putative risk of central demyelinating diseases â€“ A systematic review and meta-analysis. Vaccine, 2018, 36, 1548-1555.	1.7	37
61	Adverse Events to Food Supplements Containing Red Yeast Rice: Comparative Analysis of FAERS and CAERS Reporting Systems. Drug Safety, 2018, 41, 745-752.	1.4	24
62	Human papillomavirus vaccine and demyelinating diseasesâ€”A systematic review and meta-analysis. Pharmacological Research, 2018, 132, 108-118.	3.1	32
63	No signal of interactions between influenza vaccines and drugs used for chronic diseases: a case-by-case analysis of the vaccine adverse event reporting system and vigibase. Expert Review of Vaccines, 2018, 17, 363-381.	2.0	7
64	Diabetes is associated with decreased migraine risk: A nationwide cohort study. Cephalalgia, 2018, 38, 1759-1764.	1.8	14
65	Emilia-Romagna Study on Pregnancy and Exposure to Antiepileptic drugs (ESPEA): a population-based study on prescription patterns, pregnancy outcomes and fetal health. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 983-988.	0.9	8
66	Pharmacovigilance of sodium-glucose co-transporter-2 inhibitors: What a clinician should know on disproportionality analysis of spontaneous reporting systems. Nutrition, Metabolism and Cardiovascular Diseases, 2018, 28, 533-542.	1.1	83
67	Adverse pregnancy outcomes in women exposed to gabapentin and pregabalin: data from a population-based study. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 223-224.	0.9	21
68	Pharmacotherapy of type 2 diabetes in patients with chronic liver disease: focus on nonalcoholic fatty liver disease. Expert Opinion on Pharmacotherapy, 2018, 19, 1903-1914.	0.9	18
69	Myocarditis and pericarditis after immunization: Gaining insights through the Vaccine Adverse Event Reporting System. International Journal of Cardiology, 2018, 273, 183-186.	0.8	78
70	Multiple sclerosis as an adverse drug reaction: clues from the FDA Adverse Event Reporting System. Expert Opinion on Drug Safety, 2018, 17, 869-874.	1.0	10
71	Observational research on sodium glucose coâ€transporterâ€2 inhibitors: A real breakthrough?. Diabetes, Obesity and Metabolism, 2018, 20, 2711-2723.	2.2	18
72	Recurrence of pericarditis after influenza vaccination: a case report and review of the literature. BMC Pharmacology & Toxicology, 2018, 19, 20.	1.0	22

#	Article	IF	Citations
73	Reporting of immune checkpoint inhibitor-associated myocarditis. Lancet, The, 2018, 392, 383.	6.3	9
74	Drug-induced renal injury in neonates: challenges in clinical practice and perspectives in drug development. Expert Opinion on Drug Metabolism and Toxicology, 2017, 13, 555-565.	1.5	8
75	Use of azithromycin and risk of ventricular arrhythmia. Cmaj, 2017, 189, E560-E568.	0.9	42
76	Occurrence of Multiple Sclerosis After Drug Exposure: Insights From Evidence Mapping. Drug Safety, 2017, 40, 823-834.	1.4	6
77	Drug-Induced Arrhythmia: Bridging the Gap Between Pathophysiological Knowledge and Clinical Practice. Drug Safety, 2017, 40, 461-464.	1.4	10
78	Use of antihistamines and risk of ventricular tachyarrhythmia: a nested case-control study in five European countries from the ARITMO project. European Journal of Clinical Pharmacology, 2017, 73, 1499-1510.	0.8	13
79	Adverse events with sodium-glucose co-transporter-2 inhibitors: AÂglobal analysis of international spontaneous reporting systems. Nutrition, Metabolism and Cardiovascular Diseases, 2017, 27, 1098-1107.	1.1	31
80	Prescribing pattern of antipsychotic drugs during the years 1996â€“2010: a populationâ€based database study in Europe with a focus on torsadogenic drugs. British Journal of Clinical Pharmacology, 2016, 82, 487-497.	1.1	27
81	Prescription patterns of antiepileptic drugs in young women: development of a tool to distinguish between epilepsy and psychiatric disorders. Pharmacoepidemiology and Drug Safety, 2016, 25, 763-769.	0.9	5
82	Stroke, Migraine and Triptans: From Bedside to Bench. EBioMedicine, 2016, 6, 14-15.	2.7	1
83	Dipeptidyl peptidase-4 inhibitors and heart failure: Analysis of spontaneous reports submitted to the FDA Adverse Event Reporting System. Nutrition, Metabolism and Cardiovascular Diseases, 2016, 26, 380-386.	1.1	30
84	Safety Meta-Analysis. Journal of the American College of Cardiology, 2016, 67, 2193.	1.2	4
85	Switching among Equivalents in Chronic Cardiovascular Therapies: â€˜Real Worldâ€™ Data from Italy. Basic and Clinical Pharmacology and Toxicology, 2016, 118, 63-69.	1.2	1
86	Introduction to drug utilization research. , 2016, , 1-12.		20
87	Drug utilization research in the area of cardiovascular medicines. , 2016, , 284-293.		1
88	The Contribution of National Spontaneous Reporting Systems to Detect Signals of Torsadogenicity: Issues Emerging from the ARITMO Project. Drug Safety, 2016, 39, 59-68.	1.4	25
89	Authorsâ€™ Reply to Alain Braillonâ€™s Comment on â€œThe Contribution of National Spontaneous Reporting Systems to Detect Signals of Torsadogenicity: Issues Emerging from the ARITMO Projectâ€. Drug Safety, 2016, 39, 367-368.	1.4	0
90	Appropriateness of Proton Pump Inhibitor prescription in patients admitted to hospital: Attitudes of general practitioners and hospital physicians in Italy. European Journal of Internal Medicine, 2016, 30, 31-36.	1.0	23

#	Article	IF	Citations
91	Response to comment on: â€œantibiotic use varies substantially among adultsâ€”a crossâ€‘national study from five European Countries in the ARITMO projectâ€. Infection, 2016, 44, 135-141.	2.3	1
92	Clinically important drugâ€“drug interactions in polyâ€treated elderly outpatients: a campaign to improve appropriateness in general practice. British Journal of Clinical Pharmacology, 2015, 80, 1411-1420.	1.1	27
93	Social and Clinical Descriptors of Antipsychotic Prescription. International Journal of Psychiatry in Medicine, 2015, 49, 45-62.	0.8	5
94	Trends in paediatric macrolide use in five European countriesâ€”a population-based study. European Journal of Clinical Pharmacology, 2015, 71, 991-999.	0.8	9
95	Comment on: â€œPharmacokinetics in Patients with Chronic Liver Disease and Hepatic Safety of Incretin-Based Therapies for the Management of Type 2 Diabetes Mellitusâ€. Clinical Pharmacokinetics, 2015, 54, 447-448.	1.6	4
96	Liver injury with novel oral anticoagulants: assessing postâ€marketing reports in the US Food and Drug Administration adverse event reporting system. British Journal of Clinical Pharmacology, 2015, 80, 285-293.	1.1	66
97	Antibiotic use varies substantially among adults: a cross-national study from five European Countries in the ARITMO project. Infection, 2015, 43, 453-472.	2.3	32
98	Drug-Induced Renal Damage in Preterm Neonates: State of the Art and Methods for Early Detection. Drug Safety, 2015, 38, 535-551.	1.4	29
99	Paraesthesia after Local Anaesthetics: An Analysis of Reports to the <scp>FDA</scp> Adverse Event Reporting System. Basic and Clinical Pharmacology and Toxicology, 2015, 117, 52-56.	1.2	26
100	Adverse cardiovascular events associated with triptans and ergotamines for treatment of migraine: Systematic review of observational studies. Cephalalgia, 2015, 35, 118-131.	1.8	115
101	Pro-Arrhythmic Potential of Oral Antihistamines (H1): Combining Adverse Event Reports with Drug Utilization Data across Europe. PLoS ONE, 2015, 10, e0119551.	1.1	49
102	Systemic antibiotic prescribing to paediatric outpatients in 5 European countries: a population-based cohort study. BMC Pediatrics, 2014, 14, 174.	0.7	86
103	Use of phytoestrogens and effects perceived by postmenopausal women: result of a questionnaire-based survey. BMC Complementary and Alternative Medicine, 2014, 14, 262.	3.7	6
104	Pharmacological prioritisation of signals of disproportionate reporting: proposal of an algorithm and pilot evaluation. European Journal of Clinical Pharmacology, 2014, 70, 617-625.	0.8	12
105	Triptans and serious adverse vascular events: Data mining of the FDA Adverse Event Reporting System database. Cephalalgia, 2014, 34, 5-13.	1.8	38
106	Assessing liver injury associated with antimycotics: Concise literature review and clues from data mining of the FAERS database. World Journal of Hepatology, 2014, 6, 601.	0.8	59
107	Trend in SSRI-SNRI antidepressants prescription over a 6-year period and predictors of poor adherence. European Journal of Clinical Pharmacology, 2013, 69, 2095-2101.	0.8	30
108	Trends in antiarrhythmic drug use after marketing authorization of dronedarone: comparison between Emilia Romagna (Italy) and Sweden. European Journal of Clinical Pharmacology, 2013, 69, 715-720.	0.8	6

#	Article	IF	Citations
109	Antipsychotics and Torsadogenic Risk: Signals Emerging from the US FDA Adverse Event Reporting System Database. Drug Safety, 2013, 36, 467-479.	1.4	61
110	The association of pancreatitis with antidiabetic drug use: gaining insight through the FDA pharmacovigilance database. Acta Diabetologica, 2013, 50, 569-577.	1.2	101
111	Disproportionality signal of progressive multifocal leukoencephalopathy: monoclonal antibodies versus other immunosuppressants. Pharmacoepidemiology and Drug Safety, 2013, 22, 443-445.	0.9	5
112	Torsadogenic Risk of Antipsychotics: Combining Adverse Event Reports with Drug Utilization Data across Europe. PLoS ONE, 2013, 8, e81208.	1.1	45
113	Phytoestrogens in Postmenopause: The State of the Art from a Chemical, Pharmacological and Regulatory Perspective. Current Medicinal Chemistry, 2013, 21, 417-436.	1.2	109
114	Cardiovascular, Ocular and Bone Adverse Reactions Associated with Thiazolidinediones. Drug Safety, 2012, 35, 315-323.	1.4	34
115	Assessing the Association of Pioglitazone Use and Bladder Cancer Through Drug Adverse Event Reporting. Diabetes Care, 2011, 34, 1369-1371.	4.3	215
116	QT interval shortening in spontaneous reports submitted to the FDA: the need for consensus. British Journal of Clinical Pharmacology, 2011, 72, 839-841.	1.1	7
117	Excipients in medicinal products used in gastroenterology as a possible cause of side effects. Regulatory Toxicology and Pharmacology, 2011, 60, 93-105.	1.3	45
118	Cardiovascular events in statin recipients: impact of adherence to treatment in a 3-year record linkage study. European Journal of Clinical Pharmacology, 2011, 67, 407-414.	0.8	23
119	Pattern of triptan use and cardiovascular coprescription: a pharmacoepidemiological study in Italy. European Journal of Clinical Pharmacology, 2011, 67, 1283-1289.	0.8	8
120	Stronger association of drug-induced progressive multifocal leukoencephalopathy (PML) with biological immunomodulating agents. European Journal of Clinical Pharmacology, 2010, 66, 199-206.	0.8	35
121	Antimicrobials and the Risk of Torsades de Pointes. Drug Safety, 2010, 33, 303-314.	1.4	108
122	Profile of atypical-antipsychotics use in patients affected by dementia in the University Hospital of Ferrara. European Journal of Clinical Pharmacology, 2010, 66, 661-669.	0.8	10
123	Drugâ€induced torsades de pointes: data mining of the public version of the FDA Adverse Event Reporting System (AERS). Pharmacoepidemiology and Drug Safety, 2009, 18, 512-518.	0.9	121
124	Exposure to antibacterial agents with QT liability in 14 European countries: trends over an 8â€year period. British Journal of Clinical Pharmacology, 2009, 67, 88-98.	1.1	17
125	Adherence to statin therapy and patientsâ€™ cardiovascular risk: a pharmacoepidemiological study in Italy. European Journal of Clinical Pharmacology, 2008, 64, 425-432.	0.8	37
126	The hERG K+ channel: target and antitarget strategies in drug development. Pharmacological Research, 2008, 57, 181-195.	3.1	131

#	Article	IF	Citations
127	A 3 year survey on the use of antibacterial agents in five Italian hospitals. Journal of Antimicrobial Chemotherapy, 2008, 61, 953-958.	1.3	26
128	Discontinuation of and changes in drug therapy for hypertension among newly-treated patients: a population-based study in Italy. Journal of Hypertension, 2008, 26, 819-824.	0.3	183
129	Adherence to chronic cardiovascular therapies: persistence over the years and dose coverage. British Journal of Clinical Pharmacology, 2007, 63, 346-355.	1.1	30
130	An update on the first decade of the European centralized procedure: how many innovative drugs?. British Journal of Clinical Pharmacology, 2006, 62, 610-616.	1.1	55
131	Gastro-intestinal problems and concomitant medication in NSAID users: additional findings from a questionnaire-based survey in Italy. European Journal of Clinical Pharmacology, 2006, 62, 235-241.	0.8	11
132	QT prolongation through hERG K+ channel blockade: Current knowledge and strategies for the early prediction during drug development. Medicinal Research Reviews, 2005, 25, 133-166.	5.0	258
133	QT Prolongation Through hERG K+ Channel Blockade: Current Knowledge and Strategies for the Early Prediction During Drug Development. ChemInform, 2005, 36, no.	0.1	1
134	Initial treatment of hypertension and adherence to therapy in general practice in Italy. European Journal of Clinical Pharmacology, 2005, 61, 603-609.	0.8	43
135	Clinical implications of enteric and central D2 receptor blockade by antidopaminergic gastrointestinal prokinetics. Alimentary Pharmacology and Therapeutics, 2004, 19, 379-390.	1.9	238
136	Prescriptions of antidepressants in primary care in Italy: pattern of use after admission of selective serotonin reuptake inhibitors for reimbursement. European Journal of Clinical Pharmacology, 2004, 59, 825-831.	0.8	35
137	Pattern of NSAID use in the Italian general population: a questionnaire-based survey. European Journal of Clinical Pharmacology, 2004, 60, 731-738.	0.8	54
138	Antibacterial macrolides: a drug class with a complex pharmacological profile. Pharmacological Research, 2004, 50, 211-222.	3.1	48
139	Safety of Non-Antiarrhythmic Drugs that Prolong the QT Interval or Induce Torsade de Pointes. Drug Safety, 2002, 25, 263-286.	1.4	291
140	Toward a Pharmacophore for Drugs Inducing the Long QT Syndrome:Â Insights from a CoMFA Study of HERG K+Channel Blockers. Journal of Medicinal Chemistry, 2002, 45, 3844-3853.	2.9	409
141	Use of anti-asthmatic drugs in Italy: analysis of prescriptions in general practice in the light of guidelines for asthma treatment. European Journal of Clinical Pharmacology, 2002, 58, 55-59.	0.8	6
142	Non-antiarrhythmic drugs prolonging the QT interval:considerable use in seven countries. British Journal of Clinical Pharmacology, 2002, 54, 171-177.	1.1	39
143	Safety of Non-Antiarrhythmic Drugs that Prolong the QT Interval or Induce Torsade de Pointes. , 2002, 25, 263.		1
144	Organising evidence on QT prolongation and occurrence of Torsades de Pointes with non-antiarrhythmic drugs: a call for consensus. European Journal of Clinical Pharmacology, 2001, 57, 185-209.	0.8	169

#	Article	IF	Citations
145	QTc and psychotropic drugs. Lancet, The, 2000, 356, 75-76.	6.3	39
146	Data Mining Techniques in Pharmacovigilance: Analysis of the Publicly Accessible FDA Adverse Event Reporting System (AERS). , 0, , .		98
147	Evolving Roles of Spontaneous Reporting Systems to Assess and Monitor Drug Safety. , 0, , .		26